Currently, there are 61.92M common shares owned by the public and among those 57.73M shares have been available to trade.
However, the script later moved the day high at 3.8080, up 9.75%. The company’s stock has a 5-day price change of -58.60% and -50.14% over the past three months. FULC shares are trading -48.30% year to date (YTD), with the 12-month market performance down to -22.27% lower. It has a 12-month low price of $2.87 and touched a high of $13.70 over the same period. FULC has an average intraday trading volume of 1.62 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -56.44%, -57.96%, and -55.85% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Fulcrum Therapeutics Inc (NASDAQ: FULC) shares accounts for 84.26% of the company’s 61.92M shares outstanding.
It has a market capitalization of $217.78M and a beta (3y monthly) value of 2.30. The earnings-per-share (ttm) stands at -$0.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.21% over the week and 9.29% over the month.
Earnings per share for the fiscal year are expected to increase by 82.18%, and -334.51% over the next financial year. EPS should grow at an annualized rate of 16.40% over the next five years, compared to 1.09% over the past 5-year period.
Looking at the support for the FULC, a number of firms have released research notes about the stock. H.C. Wainwright stated their Neutral rating for the stock in a research note on September 13, 2024, with the firm’s price target at $17-$4. RBC Capital Mkts was of a view on September 12, 2024 that the stock is Sector Perform, while Leerink Partners gave the stock Market Perform rating on September 12, 2024, issuing a price target of $4. Cantor Fitzgerald on their part issued Neutral rating on September 12, 2024.
